Kaiser Permanente's national infectious disease leader says that the organization is working with the state and the federal government to inform them on COVID-19 vaccine supply needs.
Our Vaccine Study Center will lead an effort in searching medical records for serious reactions among patients who receive the vaccine.
In a New York Times op-ed, two emergency medicine doctors call for a public health campaign with trusted voices from the Black communities.
The development of a COVID-19 vaccine is being celebrated by frontline physicians, clinicians, nurses, and medical staff across the country.
Kaiser Permanente's national infectious disease leader underscores the safety of recently approved COVID-19 vaccines and the importance of avoiding holiday travel.
National infectious disease leader Stephen Parodi, MD, stresses the importance of avoiding holiday travel, wearing a mask, and practicing social distancing to prevent the spread of COVID-19.
In addition to communicating the safety of the Pfizer-BioNTech COVID-19 vaccine, public health messages must continue to emphasize the ongoing need for precautions to prevent the spread of COVID-19.
Kaiser Permanente’s national infectious disease leader expressed confidence in the safety and efficacy of the vaccine, given the organization’s participation in Pfizer-BioNTech COVID-19 vaccine trials.
The late-stage clinical trial will test the vaccine in 1,400 adults at 4 sites in California and Oregon.